You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

624 Results
Drug
Other Name(s): Alimta®
Apr 2023
Drug
Feb 2024
Drug
Other Name(s): Matulane®
Dec 2019
Drug
Other Name(s): Ifex® (multiple brands available)
Aug 2016
Drug
Other Name(s): Perjeta®
Sep 2022
Drug
Other Name(s): Zydelig™
Feb 2022
Drug
Other Name(s): Iclusig®
Aug 2023
Drug
Other Name(s): Ibrance™
May 2021
Drug
Other Name(s): Ninlaro™
Jun 2019
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Intent: Adjuvant
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Oct 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Intent: Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Oct 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Oct 2024

Pages